Oncocyte Announces the Launch of CLIA-validated DetermaIO™, a Novel Gene Expression-Based Immune Therapy Response Predictor, for ...
Company completes CLIA Validation of DetermaIO™, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust assay for identifying patients likely to respond to checkpoint inhibitor therapy Data presented at the SITC …